Replies to post #197134 on Biotech Values

[DewDiligence]

DSCI -23%/PM—both phase-3 trials in diabetic foot ulcers stopped for futility:

http://finance.yahoo.com/news/derma-sciences-announces-results-futility-123000711.html

DSCI had $62M of cash at 9/30/15 and the guidance is $40M of cash at 12/31/15. In other words, cash burn will remain fairly high even after shutting down the Aclerastide program.